

**EXPERTISE AND SERVICE PROVISION
QUALITY OF LABORATORIES**

**CLINICAL BIOLOGY COMMISSION
COMMITTEE OF EXPERTS**

**EXTERNAL QUALITY ASSESSMENT
IN CLINICAL BIOLOGY**

DEFINITIVE GLOBAL REPORT

**FLOW CYTOMETRY: CD34+ STEM CELL
ENUMERATION**

SURVEY 2019/2

Sciensano/CD34/26-E

Expertise and service provision
Quality of laboratories
J. Wytsmanstreet, 14
1050 Brussels | Belgium

www.sciensano.be

COMMITTEE OF EXPERTS

Sciensano					
Secretariat		PHONE:	02/642.55.22	FAX:	02/642.56.45
Dr. Bouacida L.	Scheme coordinator	PHONE:	02/642.53.83		
		e-mail:	lobna.bouacida@sciensano.be		
Dr. Vernelen K.	Alternate coordinator	PHONE:	02/642.55.29		
		e-mail:	kris.vernelen@sciensano.be		
Experts	Institute				
Dr. Bossuyt X.	UZ Leuven				
Dr. Chatelain B.	UCL Louvain				
Dr. Gothot A.	ULG Liège				
Dr. Heylen E.	ZNA Antwerpen				
Dr. Kornreich A.	Grand Hopital de Charleroi				
Dr. Mullier F.	UCL Louvain				
Dr. Nguyen P.	LHUB-ULB				
Dr. Philippe J.	UZ Gent				
Dr. Saussoy P.	UCL Cliniques St-Luc Bruxelles				
Dr. Vander Meeren S.	UZ Brussel				

A preliminary version of this report was submitted to the experts EQA Flow Cytometry on: 19/06/2019
 This report was discussed at the committee of experts EQA Flow Cytometry on: 25/06/2019

Authorisation to release report: by Lobna Bouacida, scheme coordinator, on 15/10/2019.

Bouacida Lobna 

All the reports are also available on our webpage:

https://www.wiv-isp.be/QML/activities/external_quality/rapports/ nl/rapports_annee.htm

https://www.wiv-isp.be/QML/activities/external_quality/rapports/ fr/rapports_annee.htm

TABLE OF CONTENTS

INTERPRETATION OF THE INDIVIDUAL REPORT	4
SAMPLE MATERIAL	7
PARTICIPATION.....	8
METHODOLOGY OF THE BELGIAN CLINICAL LABORATORIES.....	9
RESULTS.....	10
CONCLUSION.....	15
RECOMMENDATIONS	16
NEXT SURVEY	17

INTERPRETATION OF THE INDIVIDUAL REPORT

Besides this global report, an individual report is at your disposal via toolkit.

Below you can find information to help you interpreting this report.

The position of your quantitative results is presented on the one hand in comparison with the results from all the participants and on the other hand in comparison with the results of the laboratories using your method.

Following information is provided:

- Your result (R)
- Your method
- Global median (M_G):
central value of the results obtained by all laboratories (all methods together).
- Global standard deviation (SD_G):
measure of the spread of the results obtained by all the laboratories (all methods together).
- Global median of your method (M_M):
central value of the results obtained by the laboratories using your method.
- Standard deviation of your method (SD_M):
measure of the spread of the results obtained by the laboratories using your method.
- The coefficient of variation CV (expressed in %) for all laboratories and for the laboratories using your method:
 $CV_M = (SD_M / M_M) * 100$ (%) and $CV_G = (SD_G / M_G) * 100$ (%).
- Z score:
difference between your result and the median of your method (expressed as a number of SD): $Z_M = (R - M_M) / SD_M$ and $Z_G = (R - M_G) / SD_G$.
The result is flagged when $|Z_M| > 3$.
- U score:
relative deviation of your result from the median of your method (expressed in %):
 $U_m = ((R - M_M) / M_M) * 100$ (%) and $U_G = ((R - M_G) / M_G) * 100$ (%).
The result is flagged when $|U_M| > d$, where "d" is a parameter-dependent fixed limit, namely the percentage maximal deviation from the method median.
- A graphical interpretation of the position of your result (R), towards the results of all the participants as well as the results of the participants using your method, based on the method of Tukey, for each parameter and for each analyzed sample.

R : your result

$M_{M/G}$: median

$H_{M/G}$: percentiles 25 en 75

$I_{M/G}$: internal limits ($M \pm 2.7$ SD)

$O_{M/G}$: external limits ($M \pm 4.7$ SD)

The global graph and the one of your method are presented on the same scale, which allows you to compare them. These graphs give you a rough estimation of the position of your result (R) with respect to the medians (M_{MG}).

More information can be found in 3 brochures available on our website (only in Dutch and French):

https://www.wiv-isp.be/QML/index_nl.htm

https://www.wiv-isp.be/QML/index_fr.htm

(Choose “brochures” in the menu)

or directly on the following webpage (only in Dutch and French):

https://www.wiv-isp.be/QML/activities/external_quality/brochures/_nl/brochures.htm


https://www.wiv-isp.be/QML/activities/external_quality/brochures/_fr/brochures.htm

1. Informatiebrochure over de externe kwaliteitsevaluatieprogramma's voor klinische laboratoria (Algemene informatiebrochure over de externe evaluatie)/
Brochure d'information sur les programmes d'évaluation externe de la qualité pour les laboratoires cliniques (Brochure d'information générale sur l'évaluation externe).
2. Statistische brochure (Algemene statistische berekeningsprocedure opgesteld door Professor Albert)/
Brochure statistique (Procédure générale de calcul statistique mis au point par le professeur Albert).
3. Verwerking van gecensureerde waarden (Statistische berekeningsprocedure toegepast op de gecensureerde waarden opgesteld door Professor Albert)/
Traitement des valeurs censurées (Procédure de calcul statistique appliquée aux valeurs censurées rédigée par le Professeur Albert).

Graphical representation

Besides the tables with the results a "Box and whisker" plot is added. It contains the following elements for the methods with at least 6 participants:

- a rectangle ranging from percentile 25 (P_{25}) to percentile 75 (P_{75})
- a central line representing the median of the results (P_{50})
- a lower limit showing the smallest value $x > P_{25} - 1.5 * (P_{75} - P_{25})$
- an upper limit representing the largest value $x < P_{75} + 1.5 * (P_{75} - P_{25})$
- all points outside this interval are represented by a dot.



Corresponding limits in case of normal distribution

SAMPLE MATERIAL

Sent out specimens

The survey comprised one fresh umbilical cord blood sample (FC/16494).

The sample material was kindly provided by Hôpital Erasme, Brussels and distributed into aliquots at Sciensano. The sample material was collected into citrate-phosphate-dextrose. The samples were sent by Taxipost 24h and the laboratories were informed by e-mail of the send-out of the control material (day 0: 14th of May 2019).

The samples tested negative for HIV 1 and 2, hepatitis B surface antigen and hepatitis C. Homogeneity was confirmed on the basis of WBC count.

Requested analyses

The participants were asked to perform flow cytometric CD34+ stem cell enumeration and to indicate the date of receipt, the date of acquisition, and to provide details of the type of flow cytometer, the sample preparation technique, the source of antibodies, the gating strategy, and the data analysis software used.

Since the samples were not stabilised, the laboratories were asked to perform sample testing as soon as possible upon receipt.

PARTICIPATION

Twenty-four Belgian clinical laboratories participated in this survey.

METHODOLOGY OF THE BELGIAN CLINICAL LABORATORIES

Sixteen laboratories (67%) used a single platform approach for determining the absolute CD34+ cell count. Of these laboratories, 9 used Trucount technology (BD Biosciences), 5 Flow-Count or Stem-count beads (Beckman-Coulter) and 1 Perfect-Count microspheres (Cytognos). One participant used a volumetric single platform approach (MACSQuant analyzer (Miltenyi Biotec)).

The next table gives an overview of the **flow cytometers** used:

Flow cytometer	Number of laboratories
BD Biosciences FACSCanto II	14
Beckman-Coulter Navios	7
Beckman-Coulter Cytomics FC 500	2
Miltenyi Biotec MACSQuant analyzer	1

Sample preparation

Twelve participants used a sample volume of 50 µL and 10 participants a sample volume of 100 µL. Two participants used other volumes: 25 µL for one and 30 µL for the other. All participants used a lyse no wash method.

The following table summarises the lysing reagents used:

Lysing reagent	Number of laboratories
Ammonium chloride (NH ₄ Cl)	7
BD Biosciences Pharm Lyse	5
Beckman-Coulter VersaLyse	4
Beckman-Coulter Ammonium chloride	3
BD Biosciences Ammonium chloride lysing solution	2
BD Biosciences FACS Lyse	1
Qiagen EL-buffer	1
Cytognos Quicklysis	1

Monoclonal antibodies

All but 2 laboratories (PC5.5/PE-Cy5.5, APC) used a phycoerythrin (PE)-conjugated CD34 monoclonal antibody. All but 5 participants (Horizon V500 (n=3), Krome Orange, VioBlue) used a fluorescein isothiocyanate (FITC)-conjugated CD45 monoclonal antibody.

Viability

88% of the laboratories evaluated CD34+ cell viability using 7-AAD (7-Aminoactinomycin D, n=20) or TO-PRO-3 (n=1).

Gating strategy

With 3 exceptions (Beckman-Coulter Stem-Kit (1), BD Biosciences ProCount Kit (1), BD Biosciences Stem Cell Enumeration Kit (1)), all participants applied the ISHAGE (International Society of Hematotherapy and Graft Engineering) gating protocol.

RESULTS

All laboratories received the samples on day 1 or 2. Twenty-one laboratories (88%) received the samples on day 1 and three (13%) received them on day 2.

79% of the laboratories (n=19) performed the analyses on day 1, 13% on day 2 (n=3) and 8% on day 3 (n=2).

Since the samples are fresh and not stabilised, it is extremely important to perform sample testing as soon as possible upon receipt.



Statistics for the evaluation are solely based on the results of the Belgian clinical laboratories that performed the analyses on day 1 or 2 (n=22).



The median % viable CD34+ cells within total WBC was 0.118% with a CV of 17.0%. The median absolute viable CD34+ cell count was 5.5 cells/ μ L with a CV of 21.9%.

FC 16494

	Median	CV %	P25	P75	Range	N
% CD34+ cells within total WBC	0.118	17.0	0.100	0.127	0.046-0.195	22
Absolute CD34+ cell count (cells/ μ L)	5.5	21.9	5.1	6.7	2.0-11.0	22

The following boxplots and histograms show these data graphically:






The next table compares the results from the double (n=6) and single (n=16) platform users:

FC 16494

	Median cells/ μ L	CV %	P25 cells/ μ L	P75 cells/ μ L	Range cells/ μ L	N
Double platform	6.8	22.6	5.5	7.5	5.0-8.3	6
Single platform	5.5	11.8	5.1	6.0	2.0-11.0	16

FC16494



The median WBC count obtained by the laboratories using a double platform approach was $5.3 \times 10^9/L$ (n=6). The overall CV was 10.1%.

The next table shows the individual results ($10^9/L$) per type of haematology analyser:

Haematology analyser	FC 16494
Abbott Cell-Dyn Sapphire	5.1
	5.9
Siemens Advia 2120	4.3
Sysmex XN 3000	5.5
Sysmex XN 9000	5.1
	5680*

*unit error

The next table compares the absolute CD34+ cell counts obtained by the laboratories evaluating CD34+ cell viability (n=20) or not (n=2):



FC 16494

	Median/ Results cells/ μ L	CV %	P25 cells/ μ L	P75 cells/ μ L	Range cells/ μ L	N
Determination of viability	5.5	15.1	5.1	5.2	2.0-11.0	20
No determination of viability	6.6 8.3					2

The median viability of CD45+ cells was found to be 86% and the median viability of CD34+ cells was found to be 90%.

FC 16494

	Median %	CV %	P25 %	P75 %	Range %	N
Viability of CD45+ cells	86	7.7	80	89	69-99	20
Viability of CD34+ cells	90	7.8	89	99	53-100	17



CONCLUSION

% CD34+ cells within total WBC (n=24)

Three Belgian clinical laboratories (13%) obtained an unacceptable result (z-score >3 or <-3). One of these laboratories performed the analyses on day 3.

Absolute CD34+ cell count (n=24)

Two Belgian clinical laboratories (8%) obtained an unacceptable result (z-score >3 or <-3). One of these laboratories performed the analyses on day 3.

Participant	FC 16494 % CD34+ cells	z-score	FC 16494 CD34+ cells/ μ L	z-score
1	0.046	-3.579	2.0	-2.902
2	0.190	3.629	11.0	4.560
3*	0.195	3.869	10.4	4.079

* results obtained on day 3

RECOMMENDATIONS

The ISHAGE guidelines have been established to overcome a lack of standardization for the enumeration of CD34+ stem cells in routine clinical laboratories. Using these guidelines seems to be the best way to guarantee an acceptable inter-laboratory reproducibility for a better clinical application. Here, we will remind some features of these guidelines with referral to literature.

Sutherland et al. established the ISHAGE guidelines in 1996 (1). These are freely available on the Internet and describe in detail how to enumerate CD34+ cells with a double platform technology. The simple gating strategy that had then been validated is the basis of the one that should be used today. However, a gap that must be highlighted in this first description is how to identify the lymph/blast region. Indeed, an EQA survey published by Whitby et al. in 2012, showed that the most common error made for the correct application of the ISHAGE protocol was the omission of the lymphocyte gating P5/R5 region in region P1/R1 to place optimally the lymph-blast region P4/R4 (2). This part of the ISHAGE protocol was first described by Keeney et al. in 1998 (3). In this paper, two other crucial points were added (fluorescent counting beads and 7-AAD viability dye) to convert the ISHAGE protocol into a single-platform (SP) assay capable of determining the absolute viable CD34+ cell content of a sample using only a flow cytometer.

While the integration of viability dye (like 7-AAD) and the use of a lyse no wash procedure is strongly recommended to date, the replacement of conventional dual-platform by single-platform assay formats is still a matter of debate (4). The reason therefore is that the balance between advantage and disadvantage of this feature depend on many factors like the type of reagent used, the type of cytometer/hematology analyzer used and even the type of analysis software. However, some combinations of reagent kits/instrument platform have been tested for single platform use and the results of it are published in literature (5). Although these results confirm and extend the utility of 'single-platform ISHAGE protocols', no official guidelines have yet been published.

Anyway, the best way to evaluate the efficacy of your lab's enumeration protocol of CD34+ cells (whether it is a simple or double platform assay) is to participate to external quality controls and to revisit your protocol if you do not reach the quality expectations (6).

References

- ¹Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. *International Society of Hematotherapy and Graft Engineering. J Hematother* 1996;3:213-26.
- ²Whitby A, Whitby L, Fletcher M, Reilly, JT, Sutherland DR, Keeney M, Barnett D. ISHAGE protocol: Are we doing it correctly? *Cytometry Part B* 2012; 82B: 9-17.
- ³Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. *International Society of Hematotherapy and Graft Engineering. Cytometry* 1998; 34: 61-70.
- ⁴Gratama J, Orfao A, Barnett D, Brando B, Huber A, Janossy G, *et al.* Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. *Cytometry (Commun Clin Cytom)* 1998;34:128-42
- ⁵Sutherland DR, Nayyar R, Acton E, Giftakis A, Dean S, Mosiman VL. Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto cytometers. *Cytotherapy* 2009;11:595-605.
- ⁶Levering W, Preijers F, van Wieringen W, Kraan J, van Beers W, Sintnicolaas K, van Rhenen D, Gratama J. Flow cytometric CD34+ stem cell enumeration: lessons from nine years' external quality assessment within the Benelux. *Cytometry Part B* 2007; 72B:178-88.

Pharm. Hugues Jacqmin, Prof. F. Mullier and Prof. B. Chatelain
CHU UCL Namur

NEXT SURVEY

The next survey is scheduled for the **19th of November 2019**.

END

© Sciensano, Brussels 2019.

This report may not be reproduced, published or distributed without the consent of Sciensano. The laboratories' individual results are confidential. They are not passed on by Sciensano to third parties, nor to members of the Commission, the expert committees or the working group EQA.